VIRX - Viracta Therapeutics GAAP EPS of -$0.31 beats by $0.02 March, 16 2022 08:56 AM Viracta Therapeutics Inc. Viracta Therapeutics press release (NASDAQ:VIRX): Q4 GAAP EPS of -$0.31 beats by $0.02. Cash balance of $103.6 million as of December 31, 2021. For further details see: Viracta Therapeutics GAAP EPS of -$0.31 beats by $0.02